Tissue matrices comprising placental stem cells, and methods of making the same

• US 7,311,904 B2
• Filed: 02/13/2002
• Issued: 12/25/2007
• Est. Priority Date: 02/14/2001
• Status: Expired due to Term

• Current Assignee: Celularity, Inc.
• Original Assignee: Anthrogenesis Corporation (Bristol-Myers Squibb Company)
• Inventors: Hariri, Robert J.
• Primary Examiner(s): LI, QIAN JANICE
• Application Number:
  US10/074,976
• Publication Number:
  US 20020160510A1
• Time in Patent Office: 2,141 Days
• Field of Search: 435/325, 435/376, 435/1.1, 435/379, 623/11.11
• US Class Current: 424/93.1
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/50 Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
• CPC Class Codes: A61L 2430/34 for soft tissue reconstruction
• CPC Class Codes: A61L 27/3695 characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this A61L27/3687, A61L27/3691 take precedence
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61M 1/02 Blood transfusion apparatus blood infusion by syringes A61M5/14
• CPC Class Codes: A61M 2202/0462 Placental blood, umbilical cord blood
• CPC Class Codes: A61M 2210/1458 Placenta
• CPC Class Codes: A61M 2210/1466 Umbilical cord
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C12N 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 2513/00 3D culture
• CPC Class Codes: C12N 2533/90 Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
• CPC Class Codes: C12N 5/0068 General culture methods using substrates for specific animal cell type C12N5/06
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)
• CPC Class Codes: C12N 5/0678 Stem cells; Progenitor cells; Precursor cells

Abstract

A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.

Claims

1. A tissue matrix comprising placental stem cells, wherein the placental stem cells are CD10⁺, CD29⁺, CD34⁻

, CD44⁺, CD45⁻

, CD54⁺, CD90⁺, SH2⁺, SH3⁺, and SH4⁺;

wherein said placental stem cells are additionally OCT-4⁺, SSEA3⁻

or SSEA4⁻

; and

wherein said tissue matrix is made by a method comprising seeding human placental stem cells into or onto a decellularized or synthetic tissue matrix, wherein said stem cells are from a human placenta that has been drained of cord blood and perfused to remove residual blood.

2. A method of making a tissue matrix, comprising seeding human placental stem cells into or onto a decellularized or synthetic tissue matrix, wherein said stem cells are from a human placenta that has been drained of cord blood and perfused to remove residual blood, wherein said placental stem cells are CD34⁻

, SSEA3⁻

, SSEA4⁻

, and OCT-4⁺.

3. A method of making a tissue matrix, comprising seeding human placental stem cells into or onto a decellularized or synthetic tissue matrix, wherein said stem cells are from a human placenta that has been drained of cord blood and perfused to remove residual blood, wherein said placental stem cells are CD10⁺, CD29⁺, CD34⁻

, CD44⁻

, CD45⁻

, CD54⁺, CD90⁺, SH2⁺, SH3⁺, and SH4⁺; and

wherein said placental stem cells are additionally OCT-4⁺, SSEA3⁻

or SSEA4⁻

.

4. A decellularized or synthetic tissue matrix comprising human placental stem cells, wherein the placental stem cells are CD34⁻

, SSEA3⁻

, SSEA4⁻

, and OCT-4⁺.

5. A decellularized or synthetic tissue matrix comprising human placental stem cells, wherein the placental stem cells are CD34⁻

, CD10⁺, CD29⁺, CD34⁻

, CD44⁺, CD45⁻

, CD54⁺, CD90⁺, SH2⁺, SH3⁺, and SH4⁺; and

wherein said placental stem cells are additionally OCT-4⁺, SSEA3⁻

or SSEA4⁻

.